NASDAQ:DCTH Delcath Systems (DCTH) Stock Price, News & Analysis → The AI Bottleneck No One is Talking About (From The Bull Report) (Ad) Free DCTH Stock Alerts $4.18 +0.21 (+5.29%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$3.94▼$4.3350-Day Range$3.72▼$4.7952-Week Range$2.25▼$7.99Volume144,608 shsAverage Volume203,698 shsMarket Capitalization$92.17 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Delcath Systems alerts: Email Address Delcath Systems MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside330.6% Upside$18.00 Price TargetShort InterestHealthy3.78% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.36Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.53 out of 5 starsMedical Sector422nd out of 947 stocksSurgical & Medical Instruments Industry47th out of 99 stocks 3.5 Analyst's Opinion Consensus RatingDelcath Systems has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.00, Delcath Systems has a forecasted upside of 330.6% from its current price of $4.18.Amount of Analyst CoverageDelcath Systems has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.78% of the outstanding shares of Delcath Systems have been sold short.Short Interest Ratio / Days to CoverDelcath Systems has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Delcath Systems has recently increased by 2.21%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDelcath Systems does not currently pay a dividend.Dividend GrowthDelcath Systems does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DCTH. Previous Next 2.4 News and Social Media Coverage News SentimentDelcath Systems has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Delcath Systems this week, compared to 1 article on an average week.Search Interest2 people have searched for DCTH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Delcath Systems to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Delcath Systems insiders have not sold or bought any company stock.Percentage Held by Insiders21.10% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.15% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Delcath Systems is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Delcath Systems is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About Delcath Systems Stock (NASDAQ:DCTH)Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Read More DCTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DCTH Stock News HeadlinesMarch 18, 2024 | markets.businessinsider.comDelcath Systems Appoints Martha Rook As COOMarch 18, 2024 | prnewswire.comDelcath Systems Appoints Martha S. Rook as Chief Operating OfficerMarch 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 17, 2024 | investing.comDelcath Systems secures $7 million in private placementMarch 16, 2024 | finance.yahoo.comDCTH Apr 2024 7.500 callMarch 15, 2024 | markets.businessinsider.comDelcath Announces $7 Mln Private PlacementMarch 15, 2024 | prnewswire.comDelcath Systems Announces $7 Million Private PlacementMarch 8, 2024 | prnewswire.comDelcath Systems to Participate in Upcoming Investor ConferencesMarch 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.February 22, 2024 | stockhouse.comDelcath Systems Announces Healthcare Setting Locator for HEPZATO(TM) KIT (melphalan/Hepatic Delivery System)February 22, 2024 | finance.yahoo.comDelcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)February 16, 2024 | prnewswire.comDelcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 15, 2024 | finance.yahoo.comRetail investors account for 52% of Delcath Systems, Inc.'s (NASDAQ:DCTH) ownership, while institutions account for 40%February 2, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: BioNano Genomics (BNGO), Legend Biotech (LEGN)January 31, 2024 | finance.yahoo.comDelcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024January 23, 2024 | finance.yahoo.comDelcath Systems to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select ConferenceJanuary 16, 2024 | finanznachrichten.deDelcath Systems, Inc.: Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KITJanuary 16, 2024 | msn.comDelcath launches Hepzato Kit in US for uveal melanomaJanuary 16, 2024 | finance.yahoo.comDelcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KIT™January 13, 2024 | finanznachrichten.deDelcath Systems, Inc.: Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 19, 2023 | morningstar.comDelcath Systems Inc DCTHDecember 15, 2023 | finance.yahoo.comInsider Buying: Chief Medical Officer Vojo Vukovic Acquires 40,000 Shares of Delcath Systems ...December 12, 2023 | msn.comInsiders Buying Delcath Systems And 3 Other Penny StocksDecember 12, 2023 | msn.comDelcath Systems CEO discloses purchase of 34K sharesDecember 7, 2023 | finance.yahoo.comDelcath Systems Announces Publication by Independent Investigators of a Retrospective Analysis of Quality of Life in the Journal Melanoma ResearchNovember 29, 2023 | markets.businessinsider.comBuy Rating Affirmed for Delcath Systems on Strong Commercial Prospects and Novel Treatment PotentialNovember 17, 2023 | finanznachrichten.deDelcath Systems, Inc.: Delcath Systems Reports Third Quarter 2023 Results and Provides Business UpdateSee More Headlines Receive DCTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2023Today3/19/2024Next Earnings (Estimated)3/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:DCTH CUSIPN/A CIK872912 Webdelcath.com Phone212-489-2100Fax212-489-2102Employees52Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$21.00 Low Stock Price Target$13.00 Potential Upside/Downside+330.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,510,000.00 Net Margins-2,079.17% Pretax Margin-2,079.17% Return on Equity-2,571.64% Return on Assets-121.72% Debt Debt-to-Equity Ratio0.08 Current Ratio3.30 Quick Ratio3.11 Sales & Book Value Annual Sales$2.72 million Price / Sales33.89 Cash FlowN/A Price / Cash FlowN/A Book Value($0.58) per share Price / Book-7.21Miscellaneous Outstanding Shares22,050,000Free Float17,394,000Market Cap$92.17 million OptionableOptionable Beta0.51 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Gerard J. Michel MBA (Age 61)MS, CEO & Director Comp: $671.6kMr. John Purpura M.S. (Age 63)Chief Operating Officer Comp: $485.92kDr. Johnny John M.D. (Age 60)Senior Vice President Clinical Development & Medical Affairs Comp: $472.16kMs. Sandra Pennell (Age 45)Senior VP of Finance and Principal Financial & Accounting Officer Mr. David HoffmanGeneral Counsel, Corporate Secretary & Chief Compliance OfficerDr. Vojislav Vukovic M.D. (Age 57)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsenVVeno MedicalNASDAQ:NVNOBlueRiver AcquisitionNYSE:BLUAKORU Medical SystemsNASDAQ:KRMDMonogram OrthopaedicsNASDAQ:MGRMSEP AcquisitionNASDAQ:SEPAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 85,948 shares on 3/11/2024Ownership: 2.367%Vanguard Group Inc.Bought 85,948 shares on 2/15/2024Ownership: 2.368%Citadel Advisors LLCBought 18,300 shares on 2/15/2024Ownership: 0.000%ADAR1 Capital Management LLCBought 231,302 shares on 2/14/2024Ownership: 1.049%Northern Trust CorpBought 27,458 shares on 2/13/2024Ownership: 0.275%View All Insider TransactionsView All Institutional Transactions DCTH Stock Analysis - Frequently Asked Questions Should I buy or sell Delcath Systems stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DCTH shares. View DCTH analyst ratings or view top-rated stocks. What is Delcath Systems' stock price target for 2024? 4 analysts have issued 1 year target prices for Delcath Systems' shares. Their DCTH share price targets range from $13.00 to $21.00. On average, they anticipate the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 330.6% from the stock's current price. View analysts price targets for DCTH or view top-rated stocks among Wall Street analysts. How have DCTH shares performed in 2024? Delcath Systems' stock was trading at $4.16 at the beginning of the year. Since then, DCTH stock has increased by 0.5% and is now trading at $4.18. View the best growth stocks for 2024 here. When is Delcath Systems' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024. View our DCTH earnings forecast. How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (NASDAQ:DCTH) released its earnings results on Monday, March, 27th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by $0.10. The company had revenue of $0.64 million for the quarter, compared to analyst estimates of $1.97 million. Delcath Systems had a negative net margin of 2,079.17% and a negative trailing twelve-month return on equity of 2,571.64%. When did Delcath Systems' stock split? Delcath Systems's stock reverse split before market open on Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Delcath Systems' major shareholders? Delcath Systems' stock is owned by a variety of institutional and retail investors. Top institutional investors include AIGH Capital Management LLC (5.36%), Vivo Capital LLC (3.88%), Vanguard Group Inc. (2.37%), Vanguard Group Inc. (2.37%), Worth Venture Partners LLC (1.33%) and ADAR1 Capital Management LLC (1.05%). Insiders that own company stock include Ernest C Garcia II, Gerard J Michel, John Purpura, John Richard Sylvester, Rosalind Advisors, Inc, Sandra Pennell, Steven A J Salamon and Vojo Vukovic. View institutional ownership trends. How do I buy shares of Delcath Systems? Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DCTH) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThe world’s greatest investmentPorter & CompanyMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.